Clinical trials are an expensive and complex aspect of drug development. The ability to anticipate therapeutic response to immunotherapy prior to enrolling in a clinical trial is transformative.
At Elephas, we developed a novel platform that evaluates the likelihood of response to your treatment. For five years, Elephas focused on solving the scientific challenges that stood in the way of leveraging live tumor tissue to test response. Today, our platform:
- Uses a live core needle biopsy
- Cuts live tumor fragments using a proprietary cutting device
- Protects and maintains the tumor microenvironment via a novel hydrogel
- Solves for tumor heterogeneity leveraging a sequential treatment method
- Assesses response to ICI treatment via cytokine response
- Provides a detailed report on cytokine activation
Importantly, the platform is compatible with established functional assays as well as non-destructive spatial imaging, enabling researchers to characterize clinical response to ICI longitudinally.
